| Literature DB >> 32384904 |
Zhenhuang Zhuang1, Meng Gao1, Ruotong Yang1, Nan Li1,2, Zhonghua Liu3, Weihua Cao4, Tao Huang5,6,7.
Abstract
BACKGROUND: Observational studies have shown that moderate-to-vigorous physical activity (MVPA), vigorous physical activity (VPA), sedentary behaviours, and sleep duration were associated with cardiovascular diseases (CVDs) and lipid levels. However, whether such observations reflect causality remain largely unknown. We aimed to investigate the causal associations of physical activity, sedentary behaviours, and sleep duration with coronary artery disease (CAD), myocardial infarction (MI), stroke and lipid levels.Entities:
Keywords: Cardiovascular diseases; Causality; Mendelian randomization; Physical activity
Mesh:
Substances:
Year: 2020 PMID: 32384904 PMCID: PMC7206776 DOI: 10.1186/s12944-020-01257-z
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Genome-wide association studies and detailed information of single nucleotide polymorphisms used as instrumental variable in the Mendelian randomization analyses of lifestyle factors in relation to cardiovascular diseases
| Traits | SNP | Ethnics | Chr | Position | Nearest gene | EA | EAF | BETA | SE | Sample size | P value | Study | Reference | Journal |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sedentary behaviours | rs26579 | Europeans | 5 | 87,985,295 | MEF2C-AS2 | G | 0.415 | 0.028 | 0.005 | 91,105 | 2.60 × 10− 09 | UK Biobank | Aiden Doherty et al.,201828 | Nat Commun |
| Sedentary behaviours | rs25966 | Europeans | 5 | 106,822,908 | EFNA5 | G | 0.531 | 0.028 | 0.005 | 91,105 | 3.00 × 10− 09 | UK Biobank | Aiden Doherty et al.,201828 | Nat Commun |
| Sedentary behaviours | rs6801032 | Europeans | 3 | 68,527,135 | LOC105377146 | A | 0.259 | 0.031 | 0.005 | 91,105 | 3.10 × 10−09 | UK Biobank | Aiden Doherty et al.,201828 | Nat Commun |
| Sedentary behaviours | rs7779206 | Europeans | 7 | 71,723,883 | CALN1 | A | 0.558 | 0.028 | 0.005 | 91,105 | 4.20 × 10−09 | UK Biobank | Aiden Doherty et al.,201828 | Nat Commun |
| MVPA | rs429358 | Europeans | 19 | 45,411,941 | APOE | T | 0.850 | −0.019 | 0.003 | 377,234 | 7.30 × 10−11 | UK Biobank | Klimentidis YC et al.,201827 | Int J Obes (Lond) |
| MVPA | rs7804463 | Europeans | 7 | 133,447,651 | EXOC4 | T | 0.530 | 0.013 | 0.002 | 377,234 | 4.10 × 10−10 | UK Biobank | Klimentidis YC et al.,201827 | Int J Obes (Lond) |
| MVPA | rs2854277 | Europeans | 6 | 32,628,084 | HLA-DQB1 | C | 0.920 | 0.027 | 0.005 | 377,234 | 1.40 × 10−08 | UK Biobank | Klimentidis YC et al.,201827 | Int J Obes (Lond) |
| MVPA | rs1379183 | Europeans | 7 | 50,237,784 | C7orf72/SPATA48 | C | 0.410 | −0.012 | 0.002 | 377,234 | 1.70 × 10−08 | UK Biobank | Klimentidis YC et al.,201827 | Int J Obes (Lond) |
| MVPA | rs3094622 | Europeans | 6 | 30,327,952 | RPP21 | A | 0.860 | 0.018 | 0.003 | 377,234 | 1.00 × 10−08 | UK Biobank | Klimentidis YC et al.,201827 | Int J Obes (Lond) |
| MVPA | rs149943 | Europeans | 6 | 28,002,388 | ZNF165 | G | 0.850 | 0.016 | 0.003 | 377,234 | 5.60 × 10−08 | UK Biobank | Klimentidis YC et al.,201827 | Int J Obes (Lond) |
| MVPA | rs2035562 | Europeans | 3 | 85,056,521 | CADM2 | A | 0.330 | −0.014 | 0.002 | 377,234 | 1.00 × 10−09 | UK Biobank | Klimentidis YC et al.,201827 | Int J Obes (Lond) |
| MVPA | rs7854466 | Europeans | 9 | 37,044,388 | PAX5 | T | 0.560 | −0.014 | 0.002 | 377,234 | 2.40 × 10−11 | UK Biobank | Klimentidis YC et al.,201827 | Int J Obes (Lond) |
| MVPA | rs1043595 | Europeans | 7 | 128,410,012 | CALU | G | 0.720 | 0.013 | 0.002 | 377,234 | 4.20 × 10−08 | UK Biobank | Klimentidis YC et al.,201827 | Int J Obes (Lond) |
| VPA | rs1248860 | Europeans | 3 | 85,015,779 | CADM2 | G | 0.480 | −0.051 | 0.007 | 261,055 | 5.30 × 10−15 | UK Biobank | Klimentidis YC et al.,201827 | Int J Obes (Lond) |
| VPA | rs2764261 | Europeans | 6 | 108,927,842 | FOXO3 | A | 0.370 | 0.030 | 0.005 | 261,055 | 5.30 × 10−08 | UK Biobank | Klimentidis YC et al.,201827 | Int J Obes (Lond) |
| VPA | rs13243553 | Europeans | 7 | 133,506,955 | EXOC4 | G | 0.610 | 0.039 | 0.007 | 261,055 | 2.40 × 10−09 | UK Biobank | Klimentidis YC et al.,201827 | Int J Obes (Lond) |
| VPA | rs3781411 | Europeans | 10 | 126,715,436 | CTBP2 | C | 0.880 | 0.058 | 0.009 | 261,055 | 1.00 × 10−10 | UK Biobank | Klimentidis YC et al.,201827 | Int J Obes (Lond) |
| VPA | rs328902 | Europeans | 7 | 35,020,843 | DPY19L1 | C | 0.690 | −0.041 | 0.006 | 261,055 | 1.30 × 10−10 | UK Biobank | Klimentidis YC et al.,201827 | Int J Obes (Lond) |
| Sleep duration | rs1191685 | Europeans | 2 | 113,811,454 | PAX8 | C | 0.370 | 2.870 | 0.470 | 44,563 | 1.06 × 10−09 | CHARGE | Daniel J. Gottlieb et al,201529 | Mol Psychiatry |
| Sleep duration | rs1823125 | Europeans | 2 | 113,806,882 | PAX8 | G | 0.260 | 3.010 | 0.500 | 45,281 | 1.71 × 10−08 | CHARGE | Daniel J. Gottlieb et al,201529 | Mol Psychiatry |
| Sleep duration | rs1807282 | Europeans | 2 | 113,826,506 | PAX8 | T | 0.260 | 2.890 | 0.490 | 46,805 | 3.91 × 10−09 | CHARGE | Daniel J. Gottlieb et al,201529 | Mol Psychiatry |
| Sleep duration | rs1964463 | Europeans | 2 | 113,785,491 | PAX8 | G | 0.250 | 2.840 | 0.500 | 45,281 | 1.07 × 10−08 | CHARGE | Daniel J. Gottlieb et al,201529 | Mol Psychiatry |
| Sleep duration | rs4587207 | Europeans | 6 | 30,874,924 | IER3 | G | 0.800 | −3.140 | 0.560 | 46,807 | 2.02 × 10−08 | CHARGE | Daniel J. Gottlieb et al,201529 | Mol Psychiatry |
| Sleep duration | rs4248149 | Europeans | 6 | 30,875,606 | IER3 | C | 0.800 | −3.080 | 0.560 | 46,810 | 3.95 × 10−08 | CHARGE | Daniel J. Gottlieb et al,201529 | Mol Psychiatry |
| Sleep duration | rs2394403 | Europeans | 6 | 30,875,848 | IER3 | T | 0.800 | −3.070 | 0.560 | 46,811 | 4.39 × 10−08 | CHARGE | Daniel J. Gottlieb et al,201529 | Mol Psychiatry |
SNP single nucleotide polymorphism; Chr chromosome; EA effect allele; EAF effect allele frequency; SE standard error; MVPA moderate-to-vigorous physical activity; VPA vigorous physical activity; CHARGE the Cohorts for Heart and Aging Research in Genomic Epidemiology
Description of cardiovascular outcomes
| Cardiometabolic factors | Consortium or study | Sample size# | Population | Year |
|---|---|---|---|---|
| Lipids | The Global Lipids Genetics | 188,578 | Trans-Ethnics | 2013 |
| Diseases | ||||
| CAD | CARDIoGRAM and CARDIoGRAMplusC4D | 60,801/123,504 | Trans-Ethnics | 2015 |
| MI | CARDIoGRAM and CARDIoGRAMplusC4D | 43,676/128,197 | Trans-Ethnics | 2015 |
| Stroke | SiGN and ISGC | 37,792/397,209 | Trans-Ethnics | 2016 |
#Reports total sample size or case/controls;
Lipids include high density lipoprotein (mg/dL), low density lipoprotein (mg/dL), total cholesterol (mg/dL), triglycerides (mg/dL)
CAD: coronary artery disease; MI: myocardial infarction; CARDIoGRAMplusC4D: the Coronary ARtery DIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) plus the Coronary Artery Disease (C4D) Genetics (CARDIoGRAMplusC4D) consortium; SiGN: the NINDS Stroke Genetics Network; ISGC: International Stroke Genetics Consortium
fig. 1Assumptions of a Mendelian randomization analysis for lifestyle factors and risk of cardiovascular diseases. Broken lines represent potential pleiotropic or direct causal effects between variables that would violate Mendelian randomization assumptions. MVPA = moderate-to-vigorous physical activity, VPA = vigorous physical activity; CAD = coronary artery disease, MI = myocardial infarction
Fig. 2Odds ratio for association of genetically predicted lifestyle factors with cardiovascular diseases. OR: odds ratio; CI: confidence internal. OR (95% CI) means risk of cardiovascular diseases per 1 SD increase of continuous factors or per 1 unit log odds increase of binary factors. SNPs = single nucleotide polymorphisms; MVPA = moderate-to-vigorous physical activity, VPA = vigorous physical activity; MI = myocardial infarction, CAD = coronary artery disease
Fig. 3Odds ratio for association of genetically predicted lifestyle factors with lipids. ES: effect size; CI: confidence internal. ES (95% CI) means risk of changes in lipids per 1 SD increase of continuous factors or per 1 unit log odds increase of binary factors. SNPs = single nucleotide polymorphisms; MVPA = moderate-to-vigorous physical activity, VPA = vigorous physical activity; HDL = high density lipoprotein, LDL = low density lipoprotein, TC = total cholesterol, TG = triglycerides